Report five PDS0301 clinical trial data readouts
Deadline not yet reached (612 days left)
- Announced
- 21 Sep 2026
- Due
- 30 Jun 2028
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Five PDS0301 data readouts anticipated between Q4 2026 and Q2 2028 across biochemically recurrent prostate cancer, metastatic castration-resistant prostate cancer, colorectal cancer with liver metastases, and Kaposi sarcoma”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 30 Jun 2028.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Language
- Expected (“expects”, “plans”)
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you PDS Biotechnology Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-PDSB-000087 · Corrections policy